Multiple Sclerosis risk of relapse reduced by 13 percent for every 2.5 ng higher level of vitamin D (under age 37)

Created July 2017

Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up

. PLoS ONE 11(6): e0156122. doi:10.1371/ journal.pone.0156122

The Vitamin D benefit was only noticed in those < age 37 Suspect a similar benefit would be noticed for those having MS for a short time (< 5 years) Only rarely can a modest level of Vitamin D undo the long-term ravages of a disease 1. See also VitaminDWiki * Multiple Sclerosis Relapsing-Remitting rate reduced 30 percent by addition of 14,000 IU vitamin D daily – RCT Nov 2016 * No multiple sclerosis relapses during pregnancy if 50,000 IU of Vitamin D weekly – RCT April 2015 * Fewer Multiple Sclerosis lesions when supplemented with Vitamin D – meta-analysis May 2017 * Multiple Sclerosis: number needed to treat with vitamin D may be as low as 1.3 – Meta-analysis Oct 2013 * Multiple Sclerosis is more likely if poor Vitamin D Receptor (4X Mexico, 3X Iran)– Feb 2017 Overview MS and vitamin D contains the following summary {include} Multiple Sclerosis and (lots of) Vitamin D - book by patient on Coimbra protocol - Feb 2016 contains protocol description {include}

📄 Download the PDF from VitaminDWiki

Anne-Hilde Muris1,2*, Joost Smolders20, Linda Rolf1,2, Lieke J. J. Klinkenberg3,

Noreen van der Linden3, Steven Meex3, Jan Damoiseaux3, Raymond Hupperts1,2

1 School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, the Netherlands,

2 Academic MS Center Limburg, Zuyderland Medical Center, Sittard, the Netherlands,

3 Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, the Netherlands

a Current address: Department of Neurology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands * a.muris@maastrichtuniversity.nl

Background and Objective

The risk of developing multiple sclerosis (MS) as well as MS disease activity is associated with vitamin D (25(OH)D) status. The relationship between the main functional disability hallmark of MS, disability progression, and 25(OH)D status is less well established though, especially not in MS patients with progressive disease.

Methods

This retrospective follow-up study included 554 MS patients with a serum baseline 25(OH) D level and Expanded Disability Status Scale (EDSS) with a minimum follow-up of three years. Logistic regressions were performed to assess the effect of baseline 25(OH)D status on relapse rate. Repeated measures linear regression analyses were performed to assess the effect on disability and disability progression.

Results

Baseline deseasonalized 25(OH)D status was associated with subsequent relapse risk (yes/no), but only in the younger MS patients (< 37.5 years; OR = 0.872, per 10 nmol/L 25 (OH)D, p = 0.041). Baseline 25(OH)D status was not significantly associated with either disability or disability progression, irrespective of MS phenotype.

Conclusion

Within the physiological range, 25(OH)D status is just significantly associated with the occurrence of relapses in younger MS patients, but is not associated with disability or disability progression over three years follow-up. Whether high dose supplementation to supra physiological 25(OH)D levels prevents disability progression in MS should become clear

Tags: Multiple Sclerosis